COVID-19 infection; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19 infection) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 045J21A, 066D21A, 039K20A and 013L20A) for COVID-19 vaccination.     Concurrent medical conditions included Immune disorder (NOS) (Common Variable Immune Disease), Type 1 diabetes mellitus, High cholesterol, Allergy to antibiotic (Vancomycin allergy) and Sulfonamide allergy (Sulfas allergy). Concomitant products included IMMUNOGLOBULIN HUMAN NORMAL (GAMUNEX C), INSULIN LISPRO (HUMALOG), SEMAGLUTIDE (OZEMPIC) and ATORVASTATIN for an unknown indication.   On 15-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19 infection). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 31-May-2022 to 05-Jun-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19 infection) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.         Patient was not taking any other medications/products within 2 weeks of starting COVID-19 treatment.  Patient had a symptoms metallic taste in mouth ever since patient started taking paxlovid to treat an active COVID-19 infection. Patient took first dose of paxlovid on 31-May-2022 at 10 PM and woke up on 01-Jun-2022 with the taste. It hasn't gone away, despite patient last dose being more than 24 hours ago. Company comment: This spontaneous case reported by a patient, concerns a 33-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious of COVID-19 infection after receiving the 4th dose of mRNA-1273 vaccine. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid) starting on 31-May-2022 for COVID-19 treatment for 6 days. Details of the onset date, lab results and symptoms of this initial COVID-19 infection was not reported. Patient experienced metallic taste in mouth ever since he started taking Paxlovid, the day after the patient took the first dose of Paxlovid. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case reported by a patient, concerns a 33-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious of COVID-19 infection after receiving the 4th dose of mRNA-1273 vaccine. It was reported that the patient was treated with Nirmatrelvir, Ritonavir (Paxlovid) starting on 31-May-2022 for COVID-19 treatment for 6 days. Details of the onset date, lab results and symptoms of this initial COVID-19 infection was not reported. Patient experienced metallic taste in mouth ever since he started taking Paxlovid, the day after the patient took the first dose of Paxlovid. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.